País: Irlanda
Língua: inglês
Origem: HPRA (Health Products Regulatory Authority)
TRIAMCINOLONE ACETONIDE, SALICYLIC ACID
Le Vet Beheer B.V.
QD07XB02
TRIAMCINOLONE ACETONIDE, SALICYLIC ACID
2.0/20.0
Cutaneous Spray Solution
POM
Canine, Feline
Triamcinolone
Corticosteroid
Authorised
2017-02-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: ACTIVE SUBSTANCES: Triamcinolone acetonide 1.77 mg Salicylic acid 17.7 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cutaneous spray, solution. Clear colourless solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Symptomatic treatment of seborrhoeic dermatitis. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to corticosteroids, salicylic acid or to any of the excipients Do not use on cutaneous ulcers. Do not use in dogs with demodicosis. Do not administer to animals weighing less than 3.5 kg body weight. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES At the beginning of treatment, existing scale and or exfoliative debris should be removed. Hair surrounding or covering the lesions may need to be clipped to enable the veterinary medicinal product to reach the affected skin. Seborrhoeic dermatitis may be a primary disorder, but can also occur as a result of underlying disorders or disease processes (e.g. allergic disorders, endocrine disorders, neoplasia). Furthermore, infections (bacterial, parasitic or fungal) commonly occur concurrently with seborrhoeic dermatitis. Therefore it is essential to identify any underlying disease process and initiate specific treatment if considered necessary. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Leia o documento completo